Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Transgene’s stock has dropped after a Phase II trial of its therapeutic vaccine candidate TG4001 (tipapkinogene sovacivec) failed to meet its primary endpoint of improvement in progression-free survival (PFS) in solid tumours.